Category: Top News

  • Helme Tobacco Returns

    Helme Tobacco Returns

    Photo: Burtsc

    Swisher announced a rebrand of its smokeless tobacco portfolio with the return of the historic Helme Tobacco Co.

    The company’s smokeless division previously fell under the Fat Lip Brands umbrella and comprises 24 individual brands, including Kayak moist snuff tobacco, Starr loose leaf chew tobacco and Navy dry snuff.

    The Helme Tobacco Co. name traces its roots back to the 1880s and founder George W. Helme, who established the snuff and chewing tobacco company in Helmetta, New Jersey, USA. By 1925, Helme was reportedly the world’s largest snuff maker. The Helme Tobacco Co. and its products became part of the Swisher family of products and brands in 1986. Swisher later branded its smokeless tobacco portfolio under Fat Lip Brands and now rebrands that portfolio under the Helme name.

    While Swisher’s corporate headquarters is based in Jacksonville, Florida, the Helme Tobacco Co. smokeless division is located in Wheeling, West Virginia.

    “This year is a historic one for Swisher as we celebrate 100 years of continuous operations in Jacksonville, Florida. We believe now is the perfect time to reintroduce this historic and prominent smokeless tobacco name to adult consumers,” said Swisher President and CEO Neil Kiely. “The Helme name is synonymous with high-quality products and reflects the unwavering commitment of the Wheeling, West Virginia team.”

    The following brands will now fall under the Helme Tobacco Co. name:

    Kayak, Creek and Gold River moist snuff tobacco; Starr, Bowie, Chattanooga Chew, Lancaster and Mailpouch chewing tobacco; and Buttercup, Checkerberry, Dixie Sweet, Honey Bee, Lorillard, Navy, Railroad Mills, Ralphs, Society, Square, Starr, Strawberry, Superior, Three Thistle, Tops and Wild Cherry dry snuff.

  • Stop & Shop to Stop Selling Tobacco

    Stop & Shop to Stop Selling Tobacco

    Credit: Flickr

    This month, Stop & Shop stores will discontinue the sale of all tobacco products, aligning with other major chains that have already ceased cigarette sales.

    The grocery retailer with 360 stores across Massachusetts, Rhode Island, Connecticut, New York, and New Jersey plans to end sales of all tobacco products at all stores by August 31 as a part of the brand’s commitment to community wellness. The changes are part of its “dedication to community wellness” and will discontinue the sale of all cigarettes and tobacco products on Saturday, August 31.

    “Our responsibility as a grocer goes far beyond our aisles, and we are committed to taking bold steps to help our associates, customers, and communities work towards better health outcomes,” said Gordon Reid, Stop & Shop president, in a statement, according to a press release.

    Public health advocates have long urged retailers to stop selling tobacco products, and some cities and states have also banned tobacco sales in pharmacies. The American Cancer Society responded that it was “pleased to partner” with Stop & Shop to end sales.

    “This is a step in the right direction toward ending Big Tobacco’s influence on kids, and we know even more can be done to reduce the toll of tobacco in our communities,” said Karen Knudsen, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network, in the statement. “We urge state lawmakers to prioritize tobacco control program funding so that those inspired to quit by this effort have the resources they need to help them succeed.”

    Previously, Walmart in 2022 announced it would stop selling cigarettes at some of its US stores. In 2014, CVS stopped selling tobacco, saying it was “inconsistent with our purpose” as a health care provider. Target ended tobacco sales in 1996.

  • ITC Judge Urges Njoy Ban

    ITC Judge Urges Njoy Ban

    Photo: JHVEPhoto

    An administrative law judge (AJL) of the International Trade Commission (ITC) has recommended a ban on importing Njoy Ace products into the United States following a patent-infringement claim filed by Juul Labs.

    Ace is the first pod-based vapor product and the only pod-based menthol vapor product authorized by the U.S. Food and Drug Administration as appropriate for the protection of public health. According to Njoy parent company Altria Group, an exclusion order banning the importation of Ace would severely limit FDA-authorized choices for adults and undermine public health.

    “Altria and NJOY respectfully disagree with the ALJ’s initial determination, and Njoy looks forward to presenting its position to the full ITC, which is expected to issue a final decision by December 23, 2024,” Altria Group wrote in a statement.

    In August 2023, Njoy filed a similar, independent patent infringement complaint against Juul with the ITC seeking a ban on the importation and sale of Juul products in the U.S. A hearing before the ALJ was held in June 2024, and an initial determination is expected in late September. A positive outcome in this case would not preclude an exclusion order against Njoy Ace from taking effect.

    “We continue to work to bring this issue to resolution,” Altria wrote in its statement. “The parties have engaged with a mediator to attempt to negotiate a resolution of these disputes. In addition, Njoy recently filed substantial equivalence (SE) exemption requests with the FDA to allow Njoy to market an already-developed Ace product with minor modifications that we believe avoid three of the four Juul patent claims at issue in the case.”

  • PMI to Further Expand U.S. Zyn Production

    PMI to Further Expand U.S. Zyn Production

    Photo: PMI

    Philip Morris International’s Swedish Match affiliate will invest $232 million to expand the production capacity of its Owensboro, Kentucky, USA, manufacturing facility, which produces the popular Zyn nicotine pouches.

    The expansion is expected to create an additional 450 direct jobs with an ongoing annual economic impact of $277 million and 410 indirect jobs for the Commonwealth of Kentucky.

    “Philip Morris International’s Swedish Match affiliate has been an important partner and job creator in this region for many years, and I’m excited to see this incredible new investment and the 450 great job opportunities it is creating for families in Owensboro and the surrounding region,” said Kentucky Governor Andy Beshear in a statement.

    Construction of the expanded facility is already underway, including adding more production space. Progressive production increases are expected during the project, which is targeted for completion by the second quarter of 2025. The construction phase alone is expected to create nearly 2,800 jobs and have an economic impact of about $414 million.

    In addition to facility expansion and ongoing optimization of processes to increase capacity progressively over the coming quarters, the Kentucky facility will move from a 24-hour, five-days-per-week schedule to a 24-hour, seven-days-per-week schedule to boost production, starting in the fourth quarter of this year.

    The Swedish Match Owensboro facility currently has about 1,100 employees. The ongoing expansion of the facility in Kentucky is expected to provide around 900 million cans of capacity by 2025.

    In July, PMI announced an investment of $600 million over the next two years through its U.S. affiliate to open a nicotine pouch manufacturing facility in Aurora, Colorado. The Aurora facility and Owensboro expansion are designed to provide the capacity needed in the near term and midterm to meet the ferocious U.S. demand for Zyn.

  • U.S. Drug Agency Schedules Cannabis Hearing

    U.S. Drug Agency Schedules Cannabis Hearing

    The U.S. Drug Enforcement Administration (DEA) has scheduled a Dec. 2 hearing on its proposal to lower the classification of marijuana to the less dangerous level of Schedule III, according to a public announcement late Monday.

    The DEA had never issued any timeline for its process to potentially change the Schedule I classification of cannabis for the first time since the Controlled Substances Act went into effect in 1970. Still, some in the cannabis industry had hoped for a final decision before the U.S. election.

    The DEA had already received 43,000 comments on its proposal, initially made on May 21, with a comment period that closed late in July. The DEA said the comments included requests to hold a public hearing.

    DEA administrator Anne Milgram said she would determine who will participate in the hearing and name a presiding officer to run the meeting, which will take place on Dec. 2 at 9 a.m. Eastern Time at 700 Navy Drive, Arlington, Virginia.

    The government said the meeting may also be moved to a different location, continued from day to day, or recessed to a later date without notice.

  • JT to Process HTP Components in Trier

    JT to Process HTP Components in Trier

    The products prepared in Trier will be finalized at a JTI factory in Poland (pictured) Photo: JTI

    Japan Tobacco International is investing about €30 million in its Trier, Germany, factory, reports Tagesschau.

    The company plans to build a new facility that will produce components for heated-tobacco sticks. According to JTI, these products will be prepared in Trier and then integrated into heated tobacco products at a JTI plant in Poland.

    JTI-Trier Plant Manager Peter Kilburg views the investment as a sign of trust in the factory and its workforce.

    According to the company, Trier is the only JTI plant worldwide to establish such a facility. It is expected to be operational in the first quarter of 2026.

    The Trier factory employs about 1,800 people.

  • Canada to Crack Down on Pouches

    Canada to Crack Down on Pouches

    Photo: JHVEPhoto

    Nicotine pouches may be sold in Canada only by individuals working under the supervision of a pharmacist, under a new ministerial order targeting “new and emerging” nicotine-replacement therapies (NRTs). Sellers will also be required to store nicotine pouches behind the pharmacy counter.

    In addition, the new rules prohibit youth-appealing advertising or promotion and sales of nicotine pouches with flavors other than mint or menthol.

    Manufacturers will be required to print a front-of-package nicotine addiction warning as well as a clear indication of the intended use as a smoking cessation aid for adults trying to quit smoking. They must also submit mock-ups of labels and packages for all new or amended NRT licenses to ensure no youth appeal.

    The new restrictions will take force Aug. 28, 2024, though there will be a six-month transition period for the provisions on advertising and labeling. Established smoking cessation aids, such as nicotine gums, lozenges, sprays and inhalers, will continue to be available in a wide range of retail locations, with a variety of flavors.

    “Stronger measures are needed to protect youth from the harmful effects of nicotine and stop dependency before it starts,” said Minister of Health Mark Holland in a statement. “The action our government is taking will keep these products available for adults who need them to quit smoking while making sure they don’t get into the hands of youth for recreational use.”

    Public health advocates welcomed Health Canada’s announcement. “These new measures put an end to the easy access young people have had to a very addictive substance,” said Rob Cunningham, senior policy analyst with the Canadian Cancer Society, in a statement. “These restrictions will help protect youth from tobacco industry marketing and from nicotine addiction. We must avoid a repeat of the experience that has seen a dramatic increase in youth vaping.”

    Imperial Tobacco Canada (ITCAN), which makes the popular Zonnic nicotine pouches, warned that the ministerial order would derail efforts to reduce smoking rates.

    “The Minister of Health is making smoking cessation products more difficult to buy for adults who smoke and who want to quit,” said ITCAN Vice President of Corporate and Regulatory Affairs Eric Gagnon in a statement. “It goes against all logic for a country that wants to reduce smoking rates to target products that actually help people quit.”

    According to ITCAN, Zonnic is quickly becoming the leading smoking cessation aid product in locations where it’s sold. The company claims to have received testimonials suggesting that consumers have stopped or reduced smoking by using Zonnic.

    Canada regulates NRTs as drugs under the Food and Drugs Act. All NRTs must be approved by Health Canada and carry an approved health claim to be legally sold in Canada. Health Canada authorized sales of Zonnic in October 2023.

  • Tobacco Board Leaders Arrested for Fraud

    Tobacco Board Leaders Arrested for Fraud

    Photo: Taco Tuinstra

    The Zimbabwe Anti-Corruption Commission has arrested two senior executives of the Tobacco Industry and Marketing Board (TIMB) and charged them with fraud, reports The Sunday Mail.

    TIMB chairperson Patrick Devenish and TIMB CEO Meanwell Gudu are accused of extending a loan facility of over US$494,000 to Ultime Accolade Private in May 2021 without the knowledge of the tobacco industry regulator’s board.

    The pair appeared in court just a day after Gudu was acquitted of criminal abuse of office charges involving more than $2 million.

    Gudu was previously charged alongside Stuart Shanyika, a former head of special services at the TIMB, and Andrew Evaristo Matibiri, a former TIMB CEO. The trio was arrested in September 2022.

    The state alleged that the executives, acting in connivance, entered into private agreements with handpicked tobacco contractors.

    They allegedly used funds from a TIMB loan obtained from Agribank through the Reserve Bank of Zimbabwe to support these companies, contrary to provisions of the loan agreement.

  • Ignorance Is Not Bliss

    Ignorance Is Not Bliss

    Photo: bongkarn

    Professional research institutions can help nicotine companies carry out surveys that they may be reluctant to conduct themselves.

    By Neil McKeganey and Gabe Barnard

    In the 2012 Hollywood action thriller Zero Dark Thirty documenting the hunt for Osama Bin-Laden, there is a scene in which a CIA lead outlines to the president’s national security advisor the agency’s latest intelligence identifying the occupant of a fortified compound within Pakistan as possibly being the Al-Qaeda leader. On leaving the meeting and fearing that the proposed raid on the compound will have been rejected because of the risks involved, the CIA lead asks the national security advisor a critical question: Alongside the risks of the operation itself, what, he asks, are the risks of doing nothing? That scene underlines a fundamental of public policy, namely the importance of addressing both the risks of interventions as well as the risks of failing to intervene.

    And so with the tobacco industry. When it comes to tobacco products, there are few more sensitive matters than youth use of the products involved. In the world of manufacturing, selling, studying, treating and preventing tobacco consumption, the simple fact that the use of these products typically starts in the teen or preteen years makes youth use of tobacco products a hugely impactful issue. For decades, the tobacco industry has been reluctant to initiate research on teenage and underage adult use of their products, fearing that they may be accused of harvesting sensitive data on young people that may, in time, be used to market their products. While the risks of industry-supported research on youth are understandable, the risks of not undertaking that research are increasingly important.

    The consequences of initiating tobacco product use in the teen and preteen years, and of embedding a behavior that may last many decades, resulting in serious adverse health consequences, are too serious to disregard. Those involved in tobacco control, those with an interest in regulatory action and those involved in the media are all hugely interested in the results of research reporting the extent and determinants of teenage tobacco product use.

    By removing itself from research in this area, the tobacco industry repeatedly finds itself having to respond to accusations that its products are indeed being widely used by young people. By failing to support research in this area, the impression may be conveyed that industry as such are either uninterested in teen use of their products or frightened at what that research might show. That fear is understandable. If there was any doubt about the potential impact of reports of teen use of tobacco products, then think only of the fate that has befallen Juul, Puff Bar and Elf Bar. Each of these companies have been characterized as a major driver of youth vaping, and each of them have paid the price as a result.

    The ground is now changing in relation to the tobacco industry studying or supporting research in this area. There is, for example, Altria’s Underage Tobacco Use Study, gathering data on youth and underage adult use of a range of tobacco products. Not only has Altria overcome their own anxiety around research in this area, but in an extraordinary act of transparency, they have opened up the data from this study to external agencies and researchers. Similarly, other major tobacco companies are now actively considering how to undertake or support research in this area. There are multiple benefits that are likely to flow from this change. By collecting data on which products are being used by youth and young adults, tobacco companies can make a contribution both to tackling teenage tobacco use and utilizing such information in their own applications for regulatory approval where the research identifies those tobacco products that are not being used by youth and underage adults. Research in this area can help companies by providing “early warning” data on which of their products are being used by youth in which parts of the country, thereby better equipping the companies with data that can help them tackle the problem of underage tobacco use.

    In the face of a growing willingness to support youth research, the tobacco industry will still face notable barriers. Along with the large cost of undertaking research involved, there is also the fact that few in the industry have experience of undertaking research with young people.

    In both these regards, the industry can benefit from the services of professional research institutions. The Centre for Substance Use Research in Glasgow, Scotland, for example, collects detailed information on the extent to which specific named tobacco products and brands are being used by young people in the U.S. through its Tobacco Product Prevalence Survey (TPPS).

    The results of this survey have already assisted a number of companies in their submissions under the premarket tobacco product application process in the U.S. Because the TPPS study is funded by the research center rather than tobacco companies, the accusation that industry is harvesting data on young people, or that commercial interests are biasing the results, cannot be applied.

    In time, we will see more of the output of industry-supported research, with the results of that research hopefully changing the perception of an industry that while profitable is reluctant to ask the question of how widely their products are being used by young people.

  • Beyond Hot Air

    Beyond Hot Air

    Photo: Valerii Honcharuk

    Designing effective heated-tobacco products

    By Malcom Saxton

    Heated-tobacco products (HTPs) heat tobacco to a high temperature without combusting it. Intended as a tobacco harm reduction tool, good product design is a key aspect in encouraging HTP adoption among adult smokers looking to quit combustible cigarettes. Here, Malcolm Saxton, senior consultant for chemistry at Broughton, which operates a dedicated HTP testing and compliance facility, shares advice on designing an appealing HTP.

    Although a small number of brands currently dominate the HTP market, more businesses are working to bring competitive HTPs to adult smokers by investing in research, development and marketing. For example, in 2023, Japan Tobacco announced that it would invest ¥300 billion ($2.05 billion) in HTPs, with ¥200 billion allocated for marketing internationally.

    Manufacturers can create effective and competitive products by investing heavily in device design—carefully scrutinizing the product’s design requirements, its capabilities and understanding how it will achieve the desired results for target users. 

    Concept and Engineering

    One of the first steps in designing an HTP is creating a target product profile (TPP), which outlines the desired characteristics or “profile” of the product. According to the World Health Organization, TPPs “state intended use, target populations and other desired attributes of productions, including safety and efficacy-related characteristics.” Usually, manufacturers will have a vision of what they want their HTP to look like. While some may try to emulate market-leading products, others will opt for very different flavors, form factors and aesthetics.

    A growing trend in device design is personalization, with some brands launching limited edition products and providing colored panels to personalize their HTPs. Also, Bluetooth connectivity is now standard on many products, such as the latest Glo Hyper Pro, which also has an LED display and can provide real-time feedback. Another notable improvement has been reduced consumable warm-up time, which promises a more effective user experience by making the device faster to use.

    Due to the complexity, cost and time associated with designing HTPs, many manufacturers choose to work with third-party specialists. These expert partners can frame what an ideal finished product will look like and help manufacturers build a TPP that meets both user and market needs. Then, once the manufacturer and partner have agreed upon the TPP, these specialists help turn this vision into actionable targets and design parameters.

    When working toward the TPP, design considerations include the HTP’s thermal design and heating profile. During the heating process, the water in aerosol is distilled off, but unless the hot water is managed effectively, the first puff will be steam—a situation called “hot puff,” which can be dangerous for users. Consequently, manufacturers can design the device airflow to minimize the risk of hot puff by adding a preheating function to drive off the water before the user takes a puff. Another option is adding ventilation capabilities to the stick, which cools the water by drawing in air.

    Iterative Testing

    In these early stages of product realization, it’s important to capture as much data about the HTP’s design and its performance as possible. Regular, iterative tests are essential and so are short development cycles so that manufacturers can quickly capture the data, identify areas for design optimization and make the necessary changes.

    While it’s important to test multiple parameters, manufacturers must be selective with these to avoid costly delays. Some of the key parameters include total particulate matter, the amount of nicotine that the HTP delivers and the presence of a visible cloud upon inhale and exhale. This iterative stage is also a good opportunity to assess toxicological touchpoints, such as combustion markers, and whether the product meets regulatory requirements. Consequently, iterative testing allows manufacturers to understand their product’s suitability from a consumer and regulatory standpoint.

    Toxicological Considerations

    Although HTPs aim to offer smokers a less harmful alternative to combustible cigarettes, these products still carry a toxicological risk, which manufacturers must manage during the design process.

    Data from the Philip Morris International Scientific Update reports that, on average, there were 90 percent to 95 percent lower levels of harmful and potentially harmful constituents (HPHCs) in the aerosol of IQOS compared with combustible 3R4F cigarettes. However, manufacturers should treat toxicology with caution, with a WHO report noting that “some HTPs may emit unique harmful chemicals because of their distinctive characteristics and how they are used.”

    The choice of tobacco and blend is an important toxicological influence. Tobacco-specific nitrosamine—a carcinogen found on tobacco leaves—can form during the curing phase and, depending on the nitrate levels, when the device stick is heated. Therefore, it’s important to control the blend as early as possible in the development cycle, and working with an analytical testing partner can help manufacturers understand the toxicological impact of different blends.

    For a detailed understanding of toxicological risk, manufacturers can evaluate aerosol chemistry. Priority toxicant lists for cigarettes have been developed by a number of organizations, including the U.S. Food and Drug Administration, Health Canada and the WHO Study Group on Tobacco Product Regulation (TobReg). The most widely accepted list of HPHCs to test in the aerosol of HTPs, both for regulatory submission and for producing evidence of potential harm reduction, is the PMI58, a list developed specifically by Philip Morris International to focus on analytes most relevant to IQOS and, more generally, HTPs.

    Preparing for Market

    Building a strong picture of the target market can help manufacturers understand the regulatory requirements and ensure that these are built into their HTPs. Aerosol testing requirements will vary according to the regulatory framework being followed. At the most basic, the European Union and U.K. require a minimum of tar (nicotine-free dry particulate matter), nicotine and carbon monoxide to be measured. While with the far more rigorous requirements of a premarket tobacco product application, required for launch into the U.S., where a full understanding of aerosol chemistry and, more generally, the understanding of the product’s appropriateness for the protection of public health is required.

    Whichever regulatory pathway the manufacturer follows, experts, including analytical chemists, toxicologists and clinical scientists, must design testing protocols that include all the relevant parameters for regulatory approval.

    As investment in HTPs grows, manufacturers will continue to innovate and develop new designs to meet user needs. This means developing products that are both effective and comfortable to use so that smokers adopt them as smoking cessation tools. Working with an experienced partner can make the design process easier by creating an achievable TPP and helping them get the product to market.